Disease-specific miR-34a as diagnostic marker of non-alcoholic steatohepatitis in a Chinese population

Figure 1 Serum cytokeratin-18 (M30) and cytokeratin-18 (M65) levels in chronic hepatitis B (A) and non-alcoholic fatty liver disease patients, as well as non-alcoholic fatty liver and non-alcoholic steatohepatitis (B) patients. CK-18 (M30) and CK-18 (M65) showed a higher level in non-alcoholic steatohepatitis (NASH) patients than non-alcoholic fatty liver (NAFL) patients (P < 0.001), but they showed no significant difference between the non-alcoholic fatty liver disease (NAFLD) patients and chronic hepatitis B (CHB) patients. ^aP < 0.05 vs the control group; A: ^cP < 0.05 vs the CHB group; B: ^cP < 0.05 vs the NAFL group. CK-18: Cytokeratin-18.